Our promise to you:
Guaranteed product quality, expert customer support.
24x7 CUSTOMER SERVICE
CONTACT US TO ORDER
| General Information | |
| Organism | Homo sapiens, human |
| Cell Line Description | JJN-3 is a human plasma cell leukemia cell line derived from the bone marrow of a 57-year-old female patient suffering from plasma cell leukemia—an aggressive, terminal-stage variant of multiple myeloma. JJN-3 cells exhibit a lymphoblast-like morphology and grow in suspension as single cells or small clusters. The cell line secretes immunoglobulin light chains (Ig-kappa) and retains biological characteristics typical of advanced plasma cell malignancies. Genetically, JJN-3 harbors complex chromosomal rearrangements—including the t(14;16)(q32;q23) translocation that drives MAF oncogene overexpression—as well as mutations in the TP53 and KRAS genes. Given its aggressive tumor phenotype and distinct genomic alterations, JJN-3 has become a valuable in vitro model for studying the pathogenesis of multiple myeloma and plasma cell malignancies, evaluating novel therapeutic agents, investigating mechanisms of drug resistance, and screening targeted anti-myeloma drugs. |
| Tissue | Bone marrow |
| Disease | Plasma Cell Leukemia; Multiple Myeloma |
| Morphology | Lymphoblast-like |
| Gender | Female |
| Age | 57 years |
| Product Format | Frozen |
| Growth Mode | Suspension |
| Biosafety Level | 1 (Biosafety classification is based on U.S. Public Health Service Guidelines) |
| Applications | 1. Biological research on multiple myeloma and plasma cell leukemia; 2. Research on MAF oncogene regulation and KRAS/TP53 pathway signaling; 3. Evaluation of novel anti-myeloma compounds and targeted immunotherapeutic strategies; 4. High-throughput screening and functional genomics research on mechanisms of drug resistance. |
| Shipped In | Dry ice |
| Storage Temperature | −196°C |
| Characteristics | |
| Karyotype | Hyperdiploid / Aneuploid |
| Tumorigenic | Yes, forms tumors in immunocompromised mice |
| Genetic Profile | t(14;16)(q32;q23) translocation (IGH/MAF fusion); TP53 mutation; KRAS mutation |
| Expression Markers | Secretes immunoglobulin light chains (Ig-kappa); CD38 positive; CD138 positive |
| Mycoplasma Test | Negative |
| Culture Conditions and Handling | |
| Subculturing | 1. Maintain the culture by adding fresh medium or replacing the medium. 2. Establish the culture by centrifuging (1,000 rpm, 5 minutes) and resuspending the cells (at a density of 2 × 10⁵ to 4 × 10⁵ viable cells/mL). 3. Do not allow the cell concentration to exceed 1 × 10⁶ cells/mL. 4. Gently resuspend the cells to prepare a single-cell suspension before subculturing into a new culture vessel. |
| Medium Renewal | Every 2 to 3 days |
| Subcultivation Ratio | Maintain cell density between 2 × 10⁵ and 1 × 10⁶ cells/mL (split ratio approximately 1:2 to 1:4) |
| Culture Conditions | Atmosphere: Air, 95%; CO2, 5%; Temperature: 37°C |
| Cryopreservation | Complete growth medium supplemented with 5% to 10% (v/v) DMSO |
| Cat.No. | Product Name | Price |
|---|---|---|
| CSC-RR01199 | Nluc Reporter Cell Line - JJN-3 | Inquiry |
The above is only part of a part of cell line products. If you don't find the cell line you want, Creative Biogene can also provide stable cell line generation service with the best prices and fastest turnaround time for you! Contact us for more information or to request a quote.
Copyright © 2026 Creative Biogene. All rights reserved.